Acute Myeloid Leukemia Market is expected to register a CAGR close to 14% during 2019 – 2023 | Global Key Players – GENMAB A/S, GLAXOSMITHKLINE, BRISTOL MYER SQUIBB, NOVARTIS AG, ROCHE

The global Acute Myeloid Leukemia market is expected to register a CAGR of 14% during the forecast period, 2018 to 2023. North America dominates the market due to the higher awareness of the condition and the drugs that treat it, continued acceptance towards existing therapeutics

Detailed Sample Copy of Updated Analysis @ https://marketprognosis.com/sample-request/16734
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

High Incidence and prevalence rate of Acute Myeloid Leukemia
Acute Myeloid Leukemia (AML) is very common in adults which accounts for 80 percent of cases. In the United States (U.S.) the cases of AML ranges from three to five cases per 100000 population. According to a Cancer statistics in 2015 there are 20830 new cases that are diagnosed and 10,000 are died from this disease. Increasing expenditure on healthcare. Increasing expenditure on healthcare according to new data from the centers on Medicare and Medicaid Services U.S. Spent $3.2 trillion on healthcare in 2015.
Additionally, increasing investment in Research and development (R&D) and advancement in pharmacology and molecular biology to promote drug development are also driving the Global Acute Myeloid Therapeutics Market.

Key Developments in the Market
June 2017: Genmab received US FDA approval for the Darzalex for the relapsed or refractory multiple myeloma.

Key Players:
GENMAB A/S, GLAXOSMITHKLINE, BRISTOL MYER SQUIBB, NOVARTIS AG, ROCHE, CELEGENE CORPORATION AND EISAI CO LTD.

Request Discount on this repots @ https://marketprognosis.com/discount-request/16734
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

Complications related to chemotherapy
Chemotherapy treats various types of cancer. But also causes side effects differently in different patients at different locations and thus highly depend on the type of cancer, location of the cancer, drugs and their dose and general health of the individual. Common side effects of chemotherapy headaches, muscle pain, stomach pain and pain from nerve damage that is burning and numbness.
Additionally, stringent regulatory guidelines of government in the different regions for these therapeutics is restraining the global acute myeloid leukemia therapeutics market.

North America to Dominate the Market
The Global Acute Myeloid Leukemia Therapeutics market is segmented into chemotherapy and by geography. The chemotherapy segment includes CALGB 8811 regimen, hyper u2013 CVAD regimen, Oncaspar, linker regimen, nucleoside inhibitors, and others. Geographically the market has been segmented into North America, Europe, Asia-Pacific, the Middle East & Africa and South America.
North America is dominating the acute myeloid leukemia therapeutics market due to rising incidence of acute myeloid leukemia therapeutics, rise in the healthcare expenditure in that region, high investment in the development of the pipeline drugs and awareness among the people for the treatment of the acute myeloid leukemia therapeutics. Asia Pacific is expected to be the fastest growing region over the forecast period.

Enquiry Before Buying @ https://marketprognosis.com/enquiry/16734
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

About Market Prognosis
We at Market Prognosis believe in giving a crystal clear view of market dynamics for achieving success in today’s complex and competitive marketplace through our quantitative & qualitative research methods.
We help our clients identify the best market insights and analysis required for their business thus enabling them to take strategic and intelligent decision.
We believe in delivering actionable insights for your business growth and success.

Contact us:
ProgMark Pvt Ltd,
Thane - 421501
India.
Contact No: +1 973 241 5193
Email: sales@marketprognosis.com

This release was published on openPR.